Navigation Links
Signum Biosciences, Inc. Announces Commercial Launch of Arazine™
Date:7/12/2010

PRINCETON, N.J., July 12 /PRNewswire/ -- Signum Biosciences announced that its partner, Rohto Pharmaceutical Co., Ltd., has launched AFC Medirepair® with Signum's compound Arazine™ (n-acetyl-s-farnsylcysteine or AFC) in Japan.  Arazine™ is the first compound from Signum's novel anti-inflammatory platform to be commercialized from Signum's pipeline of Signal Transduction Modulators (STMs). The DRx AFC Medirepair® website can be found at: http://www.drx-web.com/aa/prod_afc.htm .

"We're excited to launch Arazine™ in the Japanese market providing a completely new and effective product for treating skin inflammation," said Signum president, Maxwell Stock.  "The commercialization of Arazine™ is a significant milestone for Signum and validates our underlying business model."

Arazine™ is a Signal Transduction Modulator (STM) with anti-inflammatory properties, which has been developed for topical skin treatment.  STMs block inflammation and neutrophil infiltration in chronic redness, acne, skin irritation, and other skin conditions by modulating G-protein signal transduction pathways.  They also act as antioxidants to neutralize free radicals and prevent UV damage, cellular degeneration and production of chemicals that cause further damage.  Arazine™ is closely followed by Signum's pipeline of compounds including SIG990 which is being developed for rosacea and other inflammatory skin conditions.

Signum and Rohto announced their strategic alliance to develop and commercialize skincare products in Japan during 2008.  Rohto gained semi-exclusive rights to develop and sell products in Japan that contain Signum's anti-inflammatory compound Arazine™.  

About Signum Biosciences.

Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from its Signal Transduction Modulation (STM) platform to modulate signal transduction imbalances. Through research on protein networks that control biological systems, Signum is developing therapeutic candidates for Alzheimer's, Parkinson's, diabetes, asthma and certain skin conditions. Signum's STM technology provides many opportunities for the development of novel consumer products and pharmaceutical candidates.

For more information please visit the Signum website: www.signumbiosciences.com

About Rohto Pharmaceutical Co., Ltd.

Rohto Pharmaceutical Co., Ltd. is among the largest manufacturers and marketers of pharmaceutical and other healthcare products in Japan. Founded in 1899, the company is based in Osaka, Japan. Production sites include facilities in the U.S., Europe, Latin America, China and Southeast Asia with product distribution to over 150 countries including all of Asia, the Americas and Europe. In 1988 the company acquired management rights to prominent U.S. manufacturer, The Mentholatum Company, Inc. Corporate sales revenue in the latest fiscal year exceeded US$ 1 Billion. The Chairman and CEO is Mr. Kunio Yamada.

For more information please visit the Rohto website: www.rohto.co.jp/global


'/>"/>
SOURCE Signum Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
2. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
3. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
4. Neurocrine Biosciences, Inc. Prices Common Stock Offering
5. Hollis-Eden Announces Name Change to Harbor BioSciences, Inc. and Ticker Symbol Change to HRBR
6. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
7. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
8. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
11. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... 2017  Bayer has awarded grants totaling more than $2 ... its prestigious Bayer Hemophilia Awards Program (BHAP). Four U.S. clinicians ... and Uniformed Services University of the Health Sciences ... Grant recipients were announced last night during a reception at ... Berlin, Germany . ...
(Date:7/11/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... on the development of oral drug delivery systems, announced ... has agreed to schedule an End-of-Phase II meeting with ... its oral insulin capsule ORMD-0801 in the treatment of ... and secondary endpoints by indicating a statistically significant lowering ...
(Date:7/10/2017)... , July 10, 2017  The tenth annual ... Boston, MA at the Sheraton Boston ... and unparalleled access to global decision makers and innovative ... 800+ life science leaders during two impactful days. BioPharm ... provides delegates with additional networking opportunities with 4,500+ life ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... July 20, 2017 , ... TCGRx announced today at ... adherence automation lines. The ATP® Mini and InspectRx® Mini are designed ... products, but at a size and price point that can help pharmacies launch ...
(Date:7/20/2017)... Charlotte, NC (PRWEB) , ... July 20, 2017 , ... ... announces the latest innovation to their product line: the AVE 2 birthing bed. , ... 2 helps bring a new level of comfort and efficiency to every phase of ...
(Date:7/20/2017)... ... July 19, 2017 , ... Western University of Health ... Administration (HRSA) grant to train predoctoral dental students in providing care to vulnerable ... underserved areas. , The Predoctoral Pediatric Training Project (PPTP), a five-year grant, recognizes ...
(Date:7/20/2017)... ... ... the Buffalo and Her Adventures”: a collection of heartwarming children’s stories. “Lucky the Buffalo ... Jr. was born in Toledo, Ohio. He attended Woodward High School. He earned ... to a brilliant woman with a caring heart named Tiina, who is a hospice nurse. ...
(Date:7/18/2017)... ... 18, 2017 , ... Doctors on Liens, the leading network ... professionals who offer the most effective and efficient care on a lien basis. ... that each patient receives prompt and courteous service, same or next day appointments, ...
Breaking Medicine News(10 mins):